Drug Shortages and Complying with FDA's 21 CFR 211.110 Guidance.

Detalles Bibliográficos
Publicado en:BioPharm International Vol. 38; no. 3; pp. 33 - 35
Autores principales: Schniepp, Susan J., LeBlanc-Rivera, Rona
Formato: pictorial questions and answers Journal Article
Publicado: MJH Life Sciences Apr2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=184485601&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 184485601
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        1542166X
        5NE
      jtl: BioPharm International
      issn: 1542166X
      maglogo: N
    pubinfo:
      dt: Apr2025
      vid: 38
      iid: 3
      pid: 54670
      pub: MJH Life Sciences
      place: Cranbury, New Jersey
    artinfo:
      ui:
        184485601
        184485601
        184485601
        184485601
      ppf: 33
      ppct: 2
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Drug Shortages and Complying with FDA's 21 CFR 211.110 Guidance.
      aug:
        au:
          Schniepp, Susan J.
          LeBlanc-Rivera, Rona
      sug:
        subj:
          Medication Shortage
          United States Food and Drug Administration
          Organizational Compliance
          Quality Control (Technology)
          Pharmaceutical Companies
          Feedback
          Manufacturing Industry
          Documentation
          Quality Improvement
          Organizational Efficiency
          Drug Approval
      pubtype: Trade Publication
      doctype:
        pictorial
        questions and answers
        Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N